[et_pb_section fb_built=”1″ admin_label=”TB Trials Landing Page – Header About” _builder_version=”4.16″ _module_preset=”default” background_color=”RGBA(0,0,0,0)” background_enable_image=”off” background_size=”initial” width=”100%” max_width=”100%” module_alignment=”center” custom_margin=”-190px||||false|false” custom_padding=”1px||13px||false|false” locked=”off” collapsed=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ admin_label=”Row – Image” _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2021\/12\/20211209-HomeBanner-scaled-1.jpg” width=”100%” max_width=”none” height=”600px” custom_margin=”|auto|||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text content_tablet=”<\/p>\n
” content_phone=”<\/p>\n
” content_last_edited=”on|phone” disabled_on=”on|on|off” admin_label=”Txt – Quote” _builder_version=”4.22.2″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_2_font_size=”18px” header_4_text_color=”#FFFFFF” background_color=”rgba(255,255,255,0.24)” transform_translate=”0px|30px” transform_translate_linked=”off” width=”60%” custom_margin=”361px|250px|45px|220px|false|false” custom_margin_tablet=”361px|250px|45px|250px|false|false” custom_margin_phone=”300px|50px||50px|false|false” custom_margin_last_edited=”on|phone” custom_padding=”10px|2px|5px|2px|false|false” header_font_tablet=”” header_font_phone=”” header_font_last_edited=”on|phone” header_2_font_tablet=”” header_2_font_phone=”” header_2_font_last_edited=”on|desktop” border_width_all=”1px” border_color_all=”#FFFFFF” box_shadow_style=”preset1″ box_shadow_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” admin_label=”Section- Intro” _builder_version=”4.16″ _module_preset=”default” width=”100%” max_width=”2680px” custom_margin=”-53px|||||” custom_padding=”4px||5px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” admin_label=”Section- Picture” _builder_version=”4.22.2″ _module_preset=”default” background_image=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2021\/11\/larm-rmah-AEaTUnvneik-unsplash-scaled-1.jpg” width=”100%” height=”500px” custom_padding=”0px|||||” collapsed=”on” global_colors_info=”{}”][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” admin_label=”Section- Impact” _builder_version=”4.21.0″ _module_preset=”default” background_enable_image=”off” width=”100%” max_width=”2680px” custom_padding=”0px|||||” collapsed=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.5″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”||7px|||” global_colors_info=”{}”]<\/p>\n
Globally, tuberculosis (TB) is the leading cause of death from a single infectious disease agent. In 2021 an estimated 1.5 million people died of TB which has meant a significant rise in mortality compared to previous years.<\/p>\n
Together with our international partners, the TB research team at the University of St Andrews is fighting the global pandemic of TB by testing and implementing innovative treatments and developing novel diagnostic and treatment monitoring tools. Our sustained research over the last 11 years (on the disease and pathogen responsible) has developed global capacity to improve TB treatment and understanding of the disease.<\/p>\n
Tuberculosis diagnosis is an important target of our research as the current tools are slow takins as much as three months to be able to tell a patients whether they have TB or not or how their ongoing disease is progressing. We have developed new tuberculosis diagnostic tests that makes the diagnosis real-time and can also quantify the number of live bacteria so that treatment can be started quickly and the response to it measured rapidly.<\/p>\n
We are also proud partners of many global organisations and consortia such as PanACEA, TB Alliance and UNITE4TB sharing the vision of a TB free world. The immense experience of our academic scientific team in clinical trials have been contributing to the realisation of our goals.<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
Our scientific group is undertaking cutting-edge laboratory and clinical research making an impactful contribution to the global fight against the TB pandemic.<\/p>\n
The research we carry out has led to the evaluation of new TB treatment and the delivery of new tools for infection control.<\/p>\n
Over the past decade we have been in the core of many international consortia, academic research and clinical studies bringing innovation to the field of TB biomarker, diagnostics and treatment strategies.<\/p>\n
From 2008 we have been members of the PanACEA network facilitating the collaboration with many African research laboratories, hospitals and universities advancing TB diagnosis, treatment and treatment response monitoring. This research has ultimately led to the development and commercialization of an assay for real-time detection of TB bacterial load and the patients\u2019 response to therapy.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row disabled_on=”off|off|off” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#302756″ width=”100%” max_width=”2680px” custom_margin=”|auto|-10px|auto||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Txt – Quote” _builder_version=”4.16″ _module_preset=”default” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” width=”100%” max_width=”2680px” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.16″ _module_preset=”default” width=”100%” max_width=”2680px” height=”360px” custom_padding=”2px|||||” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2021\/09\/team.jpg” global_colors_info=”{}”][et_pb_cta _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” min_height=”360px” height=”360px” max_height=”360px” global_colors_info=”{}” content__hover_enabled=”on|hover” content__hover=”” background__hover_enabled=”on|hover” background_color__hover=”rgba(193,0,252,0.16)” background_enable_color__hover=”on”][\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2020\/10\/PA1710219091-1.jpg” global_colors_info=”{}”][et_pb_cta _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” min_height=”360px” height=”360px” max_height=”360px” global_colors_info=”{}” content__hover_enabled=”on|hover” content__hover=”<\/p>\n
TB Alliance and Tropical Disease Foundation trials in Philippines.<\/p>\n
” background__hover_enabled=”on|hover” background_color__hover=”rgba(193,0,252,0.16)” background_enable_color__hover=”on”][\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2020\/10\/PA1710219051.jpg” global_colors_info=”{}”][et_pb_cta _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” min_height=”360px” height=”360px” max_height=”360px” global_colors_info=”{}” content__hover_enabled=”on|hover” content__hover=”<\/p>\n
MAKATI, PHILIPPINES \u2013 JANUARY 29: Nurses attend to patient\u2019s needs inside the Tropical Disease Foundation treatment facility in Makati City, Philippines JANUARY 29, 2019\u2026(Photo by Veejay Villafranca\/Getty Images for TB Alliance.<\/p>\n
” background__hover_enabled=”on|hover” background_color__hover=”rgba(193,0,252,0.16)” background_enable_color__hover=”on”][\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2020\/10\/PA1710219002.jpg” global_colors_info=”{}”][et_pb_cta _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” min_height=”360px” height=”360px” max_height=”360px” global_colors_info=”{}” content__hover_enabled=”on|hover” content__hover=”<\/p>\n
TB Alliance and Tropical Disease Foundation trials in Philippines.<\/p>\n
” background__hover_enabled=”on|hover” background_color__hover=”rgba(193,0,252,0.16)” background_enable_color__hover=”on”][\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Sct – St A Trials” _builder_version=”4.21.0″ _module_preset=”default” transform_translate=”0px|-68px” transform_translate_linked=”off” width=”100%” custom_margin=”-5px||||false|false” custom_padding=”0px||0px||false|false” box_shadow_style=”preset1″ box_shadow_spread=”-32px” locked=”off” collapsed=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ _module_preset=”default” custom_margin=”||-2px|||” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.22.2″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
The St Andrews TB research group has a history of conducting and participating in clinical trials at different levels. Our enthusiastic scientists have been making a contribution to ending TB via researching and testing novel pharmaceutical and innovative instrumental interventions to improve TB disease outcomes, diagnosis and treatment monitoring.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.5″ _module_preset=”default” max_width=”none” custom_padding=”2px|||||” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.27.5″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/poa” button_text=”POA” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” custom_css_main_element=”width:100%;” global_colors_info=”{}”][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n
<\/a>POA is a Phase III parallel\u2011group, open\u2011label, multi\u2011country, multi\u2011centre randomised controlled trial evaluating a new once\u2011weekly oral long\u2011acting antiretroviral regimen to determine whether it maintains viral suppression as effectively as daily therapy. The trial is coordinated by the University of St Andrews, with support from the University of Liverpool and Universit\u00e0 degli Studi di Torino, and is being conducted in Uganda, Kenya, C\u00f4te d\u2019Ivoire, and Zimbabwe to compare this regimen with standard first\u2011line treatment in adults who are already virologically suppressed. Feasibility, safety, and cost\u2011effectiveness will also be assessed to inform potential integration of this regimen into routine HIV care.<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.5″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/optirimoxtb\/” button_text=”OptiRiMoxTB” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” hover_enabled=”0″ custom_css_main_element=”width:100%;” global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n OptiRiMox<\/a>\u00a0is part of the\u00a0 capacity development programme within\u00a0<\/span>SimpliciTB<\/a>, and is sponsored and led by KIDH, Tanzania, managed by St Andrews, supported by<\/span>\u00a0<\/span>UCL<\/a>\u00a0and<\/span>\u00a0<\/span>Radboud UMC<\/a>.\u00a0 It is a pragmatic trial with optimized dose of rifampicin and moxifloxacin for the treatment of drug susceptible pulmonary tuberculosis (DS-TB) in primary care facilities in Blantyre, Malawi and across three other African countries namely Gabon, Mozambique, and Tanzania.<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.5″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/unite4tb-2\/” button_text=”UNITE4TB” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” custom_css_main_element=”width:100%;” global_colors_info=”{}”][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n UNITE4TB is a seven year \u20ac<\/span>185 million project.\u00a0 Thirty partners from 13 countries will deliver an efficient global clinical trails network equipped to implement phase 2 trials that conform to the highest regulatory standards.\u00a0 The goal is to deliver 2 novel phase 2 clinical trials to accelerate the development of new anti-tuberculosis drugs and regimens.\u00a0 The USTAN (University of St Andrews) group plays a key role in Work Package 7 to develop definitions for biomarkers to monitor treatment effectiveness.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.5″ _module_preset=”default” max_width=”none” custom_padding=”0px|||||” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.21.0″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/simplicitb\/” button_text=”SimpliciTB” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” custom_css_main_element=”width:100%;” global_colors_info=”{}”][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n <\/a>SimpliciTB<\/a> is a multi-centre phase 3 clinical trial evaluating a new shorter drug regimen (all-oral BPaMZ) in drug susceptible and resistant pulmonary tuberculosis across 4 continents led by\u00a0TB Alliance.<\/a><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.21.0″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/triad\/” button_text=”TRiAD” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” custom_css_main_element=”width:100%;” global_colors_info=”{}”][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n <\/a>TRiAD<\/a> \u00a0is a multi-centre, multi country study assessing the effectiveness, feasibility acceptability and cost-effectiveness of implementing a diagnostic technique for rapid selection of short drug-resistant tuberculosis.\u00a0 An additional aim is to implement the St Andrews Tuberculosis Molecular Bacterial Load Assay<\/a> (MBLA) to assess the effectiveness of therapy in real time. \u00a0The St Andrews team also provide Medical Monitoring to patients at 9 sites in 3 countries, Ethiopia, Nigeria & South Africa.<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.21.0″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/panacea\/” button_text=”PanACEA” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” custom_css_main_element=”width:100%;” global_colors_info=”{}”][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n <\/a>PanACEA<\/a> (consortium) is an international tuberculosis research association which has, and continues to, perform a series of early phase trials. St Andrews leads on Microbiology, biomarkers and modelling and assists in trial design.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.27.5″ _module_preset=”default” max_width=”none” custom_padding=”0px|||||” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.21.0″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/panbiome\/” button_text=”PanBIOME” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” custom_css_main_element=”width:100%;” global_colors_info=”{}”][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n <\/a>PanBIOME<\/a>\u00a0Biomarkers Expansion programme is piloting the novel Tuberculosis-Molecular Bacterial Load Assay (TB-MBLA) across four trial settings in three African countries, Malawi, Mozambique and Tanzania supported by funding from the\u00a0<\/span>EDCTP<\/a>\u00a0strategic primer grant.<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.21.0″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/remoxtb\/” button_text=”REMoxTB” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” custom_css_main_element=”width:100%;” global_colors_info=”{}”][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n <\/a>REMoxTB<\/a> trial is a\u00a0TB Alliance<\/a> funded global Phase 3 clinical trial, conducted at 50 sites across 9 countries and is evaluating the treatment shortening efficacy of moxifloxacin based TB therapy from 6 months to 4 months.<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.5″ _module_preset=”default” border_width_all=”1px” border_color_all=”#302756″ global_colors_info=”{}”][et_pb_button button_url=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/clinicaltrials\/stand\/” button_text=”STAND” _builder_version=”4.27.5″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#FFFFFF” button_bg_color=”#302756″ button_border_width=”0px” button_border_radius=”0px” button_font=”ABeeZee||||||||” custom_margin=”||1px|||” custom_css_main_element=”width:100%;” global_colors_info=”{}”][\/et_pb_button][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”10px|10px|10px|10px|false|false” custom_padding=”9px|||||” global_colors_info=”{}”]<\/p>\n STAND – <\/a>Shortening Treatment by Advancing Novel Drugs, is a clinical trial assessing the efficacy, safety and tolerability of a novel combination of TB drugs in varying doses and treatment lengths from 4 to 6 months in subjects with drug-sensitive (DS) pulmonary TB funded by \u00a0TB Alliance<\/a>.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" International translational research from basic science to clinical trialsMedicine makes progress through testing new treatments in randomisied controlled clinical trials. The first such trial was performed by the Medical Research Council on a new tuberculosis medicine, streptomycin, in 1946. Today the Infection Group continue in that tradition using randomised controlled clinical trials to test new […]<\/p>\n","protected":false},"author":126,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-4488","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2026-05-01 04:16:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/4488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/users\/126"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/comments?post=4488"}],"version-history":[{"count":5,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/4488\/revisions"}],"predecessor-version":[{"id":7055,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/4488\/revisions\/7055"}],"wp:attachment":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/media?parent=4488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}